Daunorubicin Hydrochloride, Cytarabine and Oblimersen Sodium in Treating Patients With Previously Untreated Acute Myeloid Leukemia

Related Clinical Trial
A Study of CG-806 in Patients With Relapsed or Refractory Acute Myeloid Leukemia Total Marrow Irradiation for Refractory Acute Leukemia Phase I Combination of Midostaurin, Bortezomib, and Chemo in Relapsed/Refractory Acute Myeloid Leukemia Therapeutic Allogeneic Lymphocytes and Aldesleukin in Treating Patients With High-Risk or Recurrent Myeloid Leukemia After Undergoing Donor Stem Cell Transplant MEK Inhibitor MEK162, Idarubicin, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Organ-Sparing Marrow-Targeted Irradiation Before Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies Decitabine and Total-Body Irradiation Followed By Donor Bone Marrow Transplant and Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Symptom-Adapted Physical Activity Intervention in Minimizing Physical Function Decline in Older Patients With Acute Myeloid Leukemia Undergoing Chemotherapy A Phase II Study Of The Farnesyltransferase Inhibitor ZANESTRA (R115777, NSC #702818, IND #58,359) In Complete Remission Following Induction And/Or Consolidation Chemotherapy In Adults With Poor-Risk Acute Myelogenous Leukemia (AML) And High-Risk Myelodysplasia (MDS) Radiolabeled BC8 Antibody, Busulfan, Cyclophosphamide Followed by Donor Stem Cell Transplant in Treating Patients With Acute Myelogenous Leukemia in First Remission 3-AP and High-Dose Cytarabine in Treating Patients With Advanced Hematologic Malignancies Busulfan and Etoposide Followed by Peripheral Blood Stem Cell Transplant and Low-Dose Aldesleukin in Treating Patients With Acute Myeloid Leukemia Vaccine Therapy and Basiliximab in Treating Patients With Acute Myeloid Leukemia in Complete Remission Decitabine in Treating Patients With Previously Untreated Acute Myeloid Leukemia GTI-2040 in Treating Patients With Relapsed, Refractory, or High-Risk Acute Leukemia, High-Grade Myelodysplastic Syndromes, or Refractory or Blastic Phase Chronic Myelogenous Leukemia PXD101 in Treating Patients With Acute Myeloid Leukemia Decitabine and Valproic Acid in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Previously Treated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Rasburicase and Allopurinol in Treating Patients With Hematologic Malignancies Lenalidomide and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Bendamustine and Idarubicin in Treating Older Patients With Previously Untreated AML or MDS Clofarabine and Cytarabine in Treating Patients With Acute Myeloid Leukemia With Minimal Residual Disease Total Marrow and Lymphoid Irradiation and Chemotherapy Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Lymphocytic or Myelogenous Leukemia Dasatinib, Cytarabine, and Idarubicin in Treating Patients With High-Risk Acute Myeloid Leukemia Sirolimus and Azacitidine in Treating Patients With High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia That is Recurrent or Not Eligible for Intensive Chemotherapy AR-42 and Decitabine in Treating Patients With Acute Myeloid Leukemia CPI-613, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Tosedostat in Combination With Cytarabine or Decitabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome Decitabine, Donor Natural Killer Cells, and Aldesleukin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Selinexor and Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Decitabine and Bortezomib in Treating Patients With Acute Myeloid Leukemia Cediranib Maleate in Treating Patients With Relapsed, Refractory, or Untreated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome SJG-136 in Treating Patients With Relapsed or Refractory Acute Leukemia, Myelodysplastic Syndromes, Blastic Phase Chronic Myelogenous Leukemia, or Chronic Lymphocytic Leukemia Daunorubicin Hydrochloride, Cytarabine and Oblimersen Sodium in Treating Patients With Previously Untreated Acute Myeloid Leukemia GTI-2040 and High-Dose Cytarabine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia Lenalidomide, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia Connect® MDS/AML Disease Registry Combined PD1 Inhibitor and Decitabine in Elderly Patients With Relapse and Refractory Acute Myeloid Leukemia Vorinostat in Treating Patients With Acute Myeloid Leukemia Clofarabine, Cytarabine, and G-CSF in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Romidepsin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Bortezomib in Treating Patients With High-Risk Acute Myeloid Leukemia in Remission Clofarabine, Cytarabine, and Filgrastim Followed by Infusion of Non-HLA Matched Ex Vivo Expanded Cord Blood Progenitors in Treating Patients With Acute Myeloid Leukemia Decitabine in Treating Children With Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia Economic Analysis of Blood Product Transfusions According to the Treatment of Acute Myeloid Leukaemia in the Elderly Comparison of Diagnostic Yield Among M-FISH, FISH Probe Panel and Conventional Cytogenetic Analysis in AML Gemtuzumab Ozogamicin in Treating Patients With Acute Myeloid Leukemia Bortezomib in Treating Young Patients With Refractory or Recurrent Leukemia Red Cell Transfusion Goals in Patients With Acute Leukemias A PALG Prospective Multicenter Clinical Trial to Compare the Efficacy of Two Standard Induction Therapies (DA-90 vs DAC) and Two Standard Salvage Regimens (FLAG-IDA vs CLAG-M) in AML Patients ≤ 60 Years Old An Efficacy and Safety Study Of Pracinostat In Combination With Azacitidine In Adults With Acute Myeloid Leukemia Fludarabine and Cytarabine as Continuous Infusion Plus G-CSF Priming for Elderly Patients With Resistant AML Phase I/II Trial of ATRA and TCP in Patients With Relapsed or Refractory AML and no Intensive Treatment is Possible Prognostic Values of Next Generation Sequencing (NGS) in Acute Myeloid Leukemia Patients With Allo-HSCT PET/MRI, 18F-FDG PET/CT and Whole Body MRI in Finding Extramedullary Myeloid Leukemia in Patients With Newly Diagnosed Acute Myeloid Leukemia Pilot Clinical Trial of Pazopanib in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or at Initial Diagnosis When no Intensive Treatment is Possible A Safety Study of SGN-CD33A in AML Patients FLAG+Ida With G-CSF Priming for Patients Younger Than 60 Years With Resistant AML Study on Number and Outcome of Pregnancy in Acute Promielocitic Leukaemia (APL) Patients Treated With Chemotherapy Biomarkers in Bone Marrow Samples From Patients With Acute Promyelocytic Leukemia Treatment Study for Children and Adolescents With Acute Promyelocitic Leukemia A Study for Improving the Outcome of Childhood Acute Promyeloid Leukemia ASCT for Relapsed APL After Molecular Remission Diagnostic Study of Patients With Acute Lymphoblastic Leukemia or Acute Promyelocytic Leukemia National Acute Promyelocytic Leukemia (APL) Observational Study NAPOLEON-Registry of the German AML Intergroup All-trans Retinoic Acid, and Arsenic +/- Idarubicin Safety, Efficacy, & Pharmacokinetic Study of Tamibarotene to Treat Patients With Relapsed or Refractory APL Randomized,International Multi-center Clinical Trial of RIF Plus RA for Non-high-risk APL Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Acute Promyelocytic Leukemia AIDA 2000 Guidelines Tretinoin, Cytarabine, and Daunorubicin Hydrochloride With or Without Arsenic Trioxide Followed by Tretinoin With or Without Mercaptopurine and Methotrexate in Treating Patients With Acute Promyelocytic Leukemia The Acute Promyelocytic Leukaemia Asian Consortium (APL-AC) Project Combined Retinoic Acid,Arsenic Trioxide and Chemo for Newly-diagnosed APL French Registry of First-line Treatment of Acute Promyelocytic Leukemia New Retinoid Agent Combined With Arsenic Trioxide for Untreated Acute Promyelocytic Leukemia Combined Tretinoin and Arsenic Trioxide for Patients With Newly Diagnosed Acute Promyelocytic Leukemia Followed by Risk-Adapted Postremission Therapy Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Promyelocytic Leukemia Treatment of Relapsed Promyelocytic Leukemia With Arsenic Trioxide (ATO) Treatment of Newly Diagnosed Patients With Acute Promyelocytic Leukemia (PETHEMA LPA 2005) Long-Term Quality of Life in Patients With Acute Promyelocytic Leukemia Tamibarotene and Arsenic Trioxide for Relapsed Acute Promyelocytic Leukemia Long-term QoL in Acute Promyelocytic Leukemia Treated With ATO or Standard Chemotherapy Treatment of Non-high-risk Acute Promyelocytic Leukemia (APL) With Realgar-Indigo Naturalis Formula (RIF) Treatment of Acute Promyelocytic Leukemia With All-Trans Retinoic Acid (ATRA) and Idarubicin (AIDA) Single Agent Arsenic Trioxide in the Treatment of Newly Diagnosed Acute Promyelocytic Leukemia Study for Patients With Newly Diagnosed, High-risk Acute Promyelocytic Leukemia Treatment Protocol for Relapsed Acute Promyelocytic Leukemia (APL) With Arsenic Study of NRX 195183 Therapy for Patients With Relapsed or Refractory Acute Promyelocytic Leukemia Oral Arsenic Trioxide for Newly Diagnosed Acute Promyelocytic Leukaemia Role of Microparticles in the Coagulopathy of Acute Promyelocytic Leukemia Proteasome Inhibition in Acute Promyelocytic Leukemia

Brief Title

Daunorubicin Hydrochloride, Cytarabine and Oblimersen Sodium in Treating Patients With Previously Untreated Acute Myeloid Leukemia

Official Title

A Phase III Study of Daunorubicin and Cytarabine +/- G3139 (Genasense, Oblimersen Sodium, NSC #683428, IND #58842), a BCL2 Antisense Oligodeoxynucleotide, in Previously Untreated Patients With Acute Myeloid Leukemia (AML) > / = 60 Years

Brief Summary

      This randomized phase III trial is studying daunorubicin, cytarabine, and oblimersen to see
      how well they work compared to daunorubicin and cytarabine in treating older patients with
      previously untreated acute myeloid leukemia. Drugs used in chemotherapy, such as daunorubicin
      and cytarabine, work in different ways to stop cancer cells from dividing so they stop
      growing or die. Oblimersen may increase the effectiveness of daunorubicin and cytarabine by
      making cancer cells more sensitive to the drugs. It is not yet known whether daunorubicin and
      cytarabine are more effective with or without oblimersen in treating acute myeloid leukemia.
    

Detailed Description

      OBJECTIVES: Primary

      I. Compare outcome, in terms of overall survival, disease-free survival, event-free survival,
      and complete response rate, in older patients with previously untreated acute myeloid
      leukemia treated with daunorubicin and cytarabine with or without oblimersen.

      Secondary I. Determine the significance of expression of select Bcl-2 family member proteins
      known to be modulated by oblimersen (e.g., Bcl-2) or which potentially mediate resistance to
      oblimersen (e.g., Bcl-XL or Mcl-1) in predicting clinical outcomes in patients treated with
      these regimens.

      II. Correlate clinical outcomes with serial changes in levels of mRNA and protein expression
      of Bcl-2, its pro-apoptotic binding partner Bax, and other anti-apoptotic Bax-binding
      proteins (e.g., Bcl-XL or Mcl-1) in patients treated with these regimens.

      III. Determine the effect of pre-treatment characteristics (e.g., morphology, cytogenetics,
      molecular features, expression of multidrug resistance molecules, functional assays of drug
      efflux, prior myelodysplastic syndromes, age, and white blood cells) on toxicity of these
      regimens and outcomes in these patients.

      OUTLINE: This is a randomized, multicenter study. Patients are randomized to 1 of 2 treatment
      arms.

      Arm I:

      Remission induction therapy: Patients receive oblimersen IV continuously on days 1-10,
      cytarabine IV continuously on days 4-10, and daunorubicin IV on days 4-6.

      Patients who achieve complete remission (CR) proceed to consolidation therapy. Patients who
      do not achieve CR receive a second course of induction therapy.

      Second remission induction therapy: Patients receive oblimersen IV continuously on days 1-8,
      cytarabine IV continuously on days 4-8, and daunorubicin IV on days 4-5.

      Patients who achieve CR proceed to consolidation therapy.

      Consolidation therapy: Patients receive oblimersen IV continuously on days 1-8 and high-dose
      cytarabine IV over 3 hours on days 4-8. Patients with a continuing CR receive a second course
      of consolidation therapy.

      Arm II:

      Remission induction therapy: Patients receive cytarabine IV continuously on days 1-7 and
      daunorubicin IV on days 1-3.

      Patients who achieve CR proceed to consolidation therapy. Patients who do not achieve CR
      receive a second course of induction therapy.

      Second remission induction therapy: Patients receive cytarabine IV continuously on days 1-5
      and daunorubicin IV on days 1 and 2.

      Patients who achieve CR proceed to consolidation therapy.

      Consolidation therapy: Patients receive high-dose cytarabine IV over 3 hours on days 1-5.
      Patients with a continuing CR receive a second course of consolidation therapy.

      In both arms, treatment continues in the absence of disease progression, unacceptable
      toxicity, failure to achieve CR after 2 courses of remission induction therapy, the presence
      of leukemic cells in the cerebrospinal fluid, leukemic regrowth, or relapse during
      consolidation therapy.

      Patients are followed every 2 months for 2 years, every 3 months for 2 years, and then
      annually for 10 years.

      PROJECTED ACCRUAL: A total of 500 patients (250 per treatment arm) will be accrued for this
      study within 4.2 years.
    

Study Phase

Phase 3

Study Type

Interventional


Primary Outcome

Overall survival (OS)


Condition

Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities

Intervention

oblimersen sodium

Study Arms / Comparison Groups

 Arm I
Description:  Remission induction therapy: Patients receive oblimersen IV continuously on days 1-10, cytarabine IV continuously on days 4-10, and daunorubicin IV on days 4-6.
Patients who achieve CR proceed to consolidation therapy. Patients who do not achieve CR receive a second course of induction therapy.
Second remission induction therapy: Patients receive oblimersen IV continuously on days 1-8, cytarabine IV continuously on days 4-8, and daunorubicin IV on days 4-5.
Patients who achieve CR proceed to consolidation therapy.
Consolidation therapy: Patients receive oblimersen IV continuously on days 1-8 and high-dose cytarabine IV over 3 hours on days 4-8. Patients with a continuing CR receive a second course of consolidation therapy.

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Biological

Estimated Enrollment

500

Start Date

December 2003


Primary Completion Date

June 2007

Eligibility Criteria

        Inclusion Criteria:

          -  DISEASE CHARACTERISTICS:

               -  Histologically confirmed acute myeloid leukemia

               -  No promyelocytic leukemia

               -  History of antecedent myelodysplasia allowed provided that the patient received
                  no prior cytotoxic therapy for myelodysplastic syndromes

          -  PRIOR CONCURRENT THERAPY:

               -  Biologic therapy

                    -  Prior growth factor and/or cytokine support allowed

                    -  No concurrent routine or prophylactic myeloid growth factors

               -  Chemotherapy

                    -  No prior chemotherapy for leukemia or myelodysplasia except under the
                       following conditions:

                    -  Emergency leukapheresis

                    -  Emergency treatment for hyperleukocytosis with hydroxyurea

                    -  No other concurrent chemotherapy

               -  Endocrine therapy

                    -  No concurrent hormones except steroids for adrenal failure or hormones for
                       non-disease-related conditions allowed (e.g., insulin for diabetes)

               -  Radiotherapy

                    -  Prior cranial radiotherapy for CNS leukostasis (1 dose only) allowed

                    -  No concurrent palliative radiotherapy

               -  Surgery

               -  Not specified

               -  Other

                    -  Concurrent enrollment on CALGB-8461, CALGB-9665, and CALGB-9760 allowed

                    -  No other concurrent investigational or commercial agents or therapies
                       intended to treat the malignancy
      

Gender

All

Ages

60 Years - N/A

Accepts Healthy Volunteers

No

Contacts

Guido Marcucci, , 

Location Countries

United States

Location Countries

United States

Administrative Informations


NCT ID

NCT00085124

Organization ID

NCI-2012-02805

Secondary IDs

CALGB-10201

Responsible Party

Sponsor

Study Sponsor

National Cancer Institute (NCI)


Study Sponsor

Guido Marcucci, Principal Investigator, Cancer and Leukemia Group B


Verification Date

June 2013